对不同类型和剂量的NSAID循环氧基因酶抑制特征的比较评估:对疗效和不良影响的影响
Kenshu Shirakawa1, Masafumi Takeno2,3, Hidekazu Kuma4,5
1Department of Anesthesiology and Pain Medicine, Dokkyo Medical University School of Medicine, Tochigi, Japan.
Pain and therapy
|December 17, 2024
概括
这项研究比较了NSAIDs临床剂量的循环氧化原酶 (COX) 抑制. 狄克洛芬雅克的使用方法
科学领域:
- 药理学 药理学是指药理学的学科.
- 药物代谢和药理动力学
- 疼痛管理 疼痛管理
背景情况:
- 非类固醇抗炎药物 (NSAIDs) 广泛用于缓解疼痛.
- 无 NSAIDs 通过抑制循环氧化酶 (COX) 酶来起作用.
- 之前的研究还没有全面比较不同NSAID配方的临床血度的COX抑制.
研究的目的:
- 评估各种NSAID配方的循环氧化原酶 (COX) 抑制活性和临床剂量的抑制率.
- 为了比较COX抑制度与临床剂量的血度.
- 为了研究不同剂型的疗效和不良影响,特别是二甲.
主要方法:
- 人类血液样本与NSAIDs (迪克洛菲纳克,切莱科西布,伊布罗芬,弗卢比,埃托多拉克) 进行了化.
- 使用ELISA量化COX抑制活性.
- 逻辑回归分析了临床剂量的最大血药物度 (Cmax) 的抑制率.
主要成果:
- 大多数NSAID在Cmax时达到>50%的COX-2抑制,除了100毫克的赛莱科西布.
- 迪克洛菲纳克的口服和假药形式显示出几乎完全的COX-2抑制,并且超过了COX-1的IC80.
- 狄克洛菲纳克的透皮配方在重复剂量时显示超过IC80的COX-2抑制,但COX-1的IC80以下.
结论:
- 高水平的COX-1抑制解释了口服/支架二二的胃肠道问题.
- 通过皮肤注射的二甲可以实现止痛效果 (IC50>COX-2抑制) 与较低的COX-1抑制.
- 透皮配方提供止痛效果与较低的Cmax相比,其他二二的形式.
相关概念视频
Drugs for Peptic Ulcer Disease: Prostaglandin Analogs as Mucosal Protective Agents
347
The gastric mucosa produces prostaglandins E2 (PGE2) and prostacyclin (PGI2), crucial in maintaining gastric health. They exert cytoprotective effects, including increasing bicarbonate secretion, releasing protective mucin, reducing gastric acid output, and preventing harmful vasoconstriction. These effects are mediated through various receptors, such as EP1, EP2, EP3, and EP4.
Non-steroidal anti-inflammatory drugs (NSAIDs) can induce peptic ulcers by inhibiting cyclooxygenase, decreasing...
Non-steroidal anti-inflammatory drugs (NSAIDs) can induce peptic ulcers by inhibiting cyclooxygenase, decreasing...
347
Time Course of Drug Effect
1.9K
The progression of a drug's impact can be analyzed by examining both the concentration-time course and the effect-time course. The concentration-time course is determined by the drug's half-life and is influenced by factors such as its pharmacokinetics, including absorption, distribution, metabolism, and elimination. The effect of the drug is often related to its concentration in the plasma and is calculated using the maximum drug effect and the plasma concentration that generates 50...
1.9K
Dose-Response Relationship: Potency and Efficacy
4.2K
The potency of a drug is the measure of its ability to produce a biological response and can be compared by looking at the half-maximum effective concentration or EC50 values of different drugs. A lower EC50 value indicates higher potency of the drug. In the dose–response curve of two antihypertensive drugs, candesartan and irbesartan, a significant difference is observed in their EC50 values. A lower EC50 value for candesartan indicates that it is more potent than irbesartan, as it...
4.2K
Bioequivalence: Overview
921
Pharmaceutical equivalents, by definition, are drug products with the same active ingredient in the same quantities, encapsulated in identical dosage forms, and intended for the same administration routes. These pharmaceutical equivalents are deemed bioequivalent if the bioavailability of the active entity in the drug preparations is similar. Moreover, pharmaceutical equivalents demonstrating bioequivalence are also regarded as therapeutically equivalent. This means that when used as directed,...
921
Therapeutic Index
4.1K
The therapeutic index of a drug is a key parameter in pharmacology that quantifies the relative safety of a drug by calculating the ratio between the dose that causes toxicity in half the population (50%) to the dose that proves to be effective for half the population (50%). It provides a spectrum of doses for a particular drug ranging from effective to potentially toxic. To illustrate, consider an anticoagulant agent like warfarin. It possesses a narrow window within its therapeutic index to...
4.1K
Drugs for Treatment of Ulcerative Colitis in IBD
119
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...
119


